Terms: = Bone cancer AND CEBPA, CEBP, 1050, C/EBP-alpha, P49715 AND Prognosis
28 results:
1. C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription.
Du M; Wang M; Liu M; Fu S; Lin Y; Huo Y; Yu J; Yu X; Wang C; Xiao H; Wang L
J Exp Clin Cancer Res; 2024 Mar; 43(1):79. PubMed ID: 38475919
[TBL] [Abstract] [Full Text] [Related]
2. The Effects of Fucoidan Derived from
Gupta D; Martinez DC; Puertas-Mejía MA; Hearnden VL; Reilly GC
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396762
[TBL] [Abstract] [Full Text] [Related]
3. High-intensity chemotherapy improved the prognosis of patients with high-grade B-cell lymphoma.
Chen Y; Cai Q; Chang Y; Zhang M; Li Z
Front Immunol; 2022; 13():1047115. PubMed ID: 36618391
[TBL] [Abstract] [Full Text] [Related]
4. Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission.
Tien FM; Tsai CH; Huang SC; Liu JH; Chen CY; Kuo YY; Chuang YK; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Wu YS; Hou MF; Wu SJ; Hsu SC; Ko BS; Chou WC; Yao M; Hou HA; Tang JL; Tien HF
Bone Marrow Transplant; 2022 Jan; 57(1):95-105. PubMed ID: 34671120
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic significance of long non coding maternally expressed gene 3 in pediatric acute myeloid leukemia.
Xue H; Gao H; Xia H; Li S; Li N; Duan Y; Ren Y; Zhang H; Liu J; Gao W
Medicine (Baltimore); 2021 Sep; 100(35):e26959. PubMed ID: 34477125
[TBL] [Abstract] [Full Text] [Related]
6. Bioinformatics integrated analysis to investigate candidate biomarkers and associated metabolites in osteosarcoma.
Wang J; Gong M; Xiong Z; Zhao Y; Xing D
J Orthop Surg Res; 2021 Jul; 16(1):432. PubMed ID: 34225733
[TBL] [Abstract] [Full Text] [Related]
7. Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study.
Myers KC; Furutani E; Weller E; Siegele B; Galvin A; Arsenault V; Alter BP; Boulad F; Bueso-Ramos C; Burroughs L; Castillo P; Connelly J; Davies SM; DiNardo CD; Hanif I; Ho RH; Karras N; Manalang M; McReynolds LJ; Nakano TA; Nalepa G; Norkin M; Oberley MJ; Orgel E; Pastore YD; Rosenthal J; Walkovich K; Larson J; Malsch M; Elghetany MT; Fleming MD; Shimamura A
Lancet Haematol; 2020 Mar; 7(3):e238-e246. PubMed ID: 31879230
[TBL] [Abstract] [Full Text] [Related]
8. Genetic alteration patterns and clinical outcomes of elderly and secondary acute myeloid leukemia.
Wang SY; Cheng WY; Mao YF; Zhu YM; Liu FJ; Ma TT; Shen Y
Hematol Oncol; 2019 Oct; 37(4):456-463. PubMed ID: 31348835
[TBL] [Abstract] [Full Text] [Related]
9. Unusual findings of acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): A multicenter study.
Gong X; Yu T; Tang Q; Fu Y; Wu J; Zhu Y; Tu H; Ge H; Lu X; Gong D; Zhao X
Int J Lab Hematol; 2019 Jun; 41(3):380-386. PubMed ID: 30793839
[TBL] [Abstract] [Full Text] [Related]
10. Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study.
Hidaka D; Onozawa M; Hashiguchi J; Miyashita N; Kasahara K; Fujisawa S; Hayase E; Okada K; Shiratori S; Goto H; Sugita J; Nakagawa M; Hashimoto D; Kahata K; Endo T; Yamamoto S; Tsutsumi Y; Haseyama Y; Nagashima T; Mori A; Ota S; Sakai H; Ishihara T; Imai K; Miyagishima T; Kakinoki Y; Kurosawa M; Kobayashi H; Iwasaki H; Shimizu C; Kondo T; Teshima T
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e469-e479. PubMed ID: 30082223
[TBL] [Abstract] [Full Text] [Related]
11. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, cebpa, and NPM1 genes in acute myeloid leukemia.
Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
[TBL] [Abstract] [Full Text] [Related]
12. Acute Myeloid Leukemia: Diagnosis and Management Based on Current Molecular Genetics Approach.
Suguna E; Farhana R; Kanimozhi E; Kumar PS; Kumaramanickavel G; Kumar CS
Cardiovasc Hematol Disord Drug Targets; 2018; 18(3):199-207. PubMed ID: 29766829
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic significance of microRNA-99a in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
Cheng Z; Zhou L; Hu K; Dai Y; Pang Y; Zhao H; Wu S; Qin T; Han Y; Hu N; Chen L; Wang C; Zhang Y; Wu D; Ke X; Shi J; Fu L
Bone Marrow Transplant; 2018 Sep; 53(9):1089-1095. PubMed ID: 29515250
[TBL] [Abstract] [Full Text] [Related]
14. Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemia.
Kamijo R; Itonaga H; Kihara R; Nagata Y; Hata T; Asou N; Ohtake S; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Ogawa S; Naoe T; Kiyoi H; Miyazaki Y
Leuk Res; 2018 Feb; 65():34-41. PubMed ID: 29306105
[TBL] [Abstract] [Full Text] [Related]
15. Development of acute myeloid leukemia in patients with untreated chronic lymphocytic leukemia.
Ito S; Fujiwara SI; Mashima K; Umino K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
Ann Hematol; 2017 May; 96(5):719-724. PubMed ID: 28144729
[TBL] [Abstract] [Full Text] [Related]
16. NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.
Struski S; Lagarde S; Bories P; Puiseux C; Prade N; Cuccuini W; Pages MP; Bidet A; Gervais C; Lafage-Pochitaloff M; Roche-Lestienne C; Barin C; Penther D; Nadal N; Radford-Weiss I; Collonge-Rame MA; Gaillard B; Mugneret F; Lefebvre C; Bart-Delabesse E; Petit A; Leverger G; Broccardo C; Luquet I; Pasquet M; Delabesse E
Leukemia; 2017 Mar; 31(3):565-572. PubMed ID: 27694926
[TBL] [Abstract] [Full Text] [Related]
17. Antitumor and Antimetastatic Activity of Synthetic Hydroxystilbenes Through Inhibition of Lymphangiogenesis and M2 Macrophage Differentiation of Tumor-associated Macrophages.
Kimura Y; Sumiyoshi M; Baba K
Anticancer Res; 2016 Jan; 36(1):137-48. PubMed ID: 26722037
[TBL] [Abstract] [Full Text] [Related]
18. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
[TBL] [Abstract] [Full Text] [Related]
19. [AML treatment strategy based on cytogenetic abnormalities and somatic mutations].
Imai Y
Rinsho Ketsueki; 2015 Oct; 56(10):1932-41. PubMed ID: 26458431
[TBL] [Abstract] [Full Text] [Related]
20. Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid Leukemia.
Sivagnanalingam U; Balys M; Eberhardt A; Wang N; Myers JR; Ashton JM; Becker MW; Calvi LM; Mendler JH
PLoS One; 2015; 10(7):e0132375. PubMed ID: 26177509
[TBL] [Abstract] [Full Text] [Related]
[Next]
